BPC-157 + Egrifta (Tesamorelin) Stack: Complete Protocol

What Are These Two Peptides and Why Combine Them?

Tesamorelin (Egrifta SV) and BPC-157 target overlapping but distinct biological pathways. Tesamorelin drives the growth hormone axis downward through the pituitary, while BPC-157 appears to sensitize peripheral tissues to GH signaling and supports vascular and connective-tissue repair independently. Practitioners combine them to address body composition, metabolic markers, and soft-tissue recovery in a single protocol.

Tesamorelin: The FDA-Approved Foundation

Tesamorelin is a stabilized analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved it in November 2010 under the brand name Egrifta for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. In the key Phase III trials (combined N=816), tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 17.8% versus 1.6% placebo at 26 weeks, measured by CT scan [1]. IGF-1 levels rose by roughly 181 mcg/L from baseline in treated patients [1].

The Endocrine Society's 2011 clinical practice guideline on adult growth hormone deficiency notes that GHRH analogues raise IGF-1 into the physiological range without the supraphysiological peaks associated with exogenous GH injections, which may reduce glucose-related adverse effects [2].

BPC-157: Mechanism and Evidence Base

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a partial sequence of human gastric juice protein BPC. It has no FDA approval and is classified as a research compound. Animal studies show it accelerates tendon-to-bone healing, reduces gut inflammation, and promotes angiogenesis through nitric oxide pathway modulation [3]. A 2018 review in the Journal of Physiology-Paris summarized rodent data showing BPC-157 upregulates growth hormone receptor (GHR) expression in peripheral tissues, which may amplify the downstream effect of tesamorelin-driven GH pulses [4].

Human data on BPC-157 are limited to one small Phase II trial in inflammatory bowel disease (NCT00281190) that showed tolerability but was never completed to efficacy endpoints [5]. That evidence gap must be stated plainly.

Mechanistic Rationale for the Combination

Tesamorelin raises systemic GH and IGF-1. BPC-157 may increase the density and sensitivity of GHR in tendons, gut mucosa, and skeletal muscle. The theoretical result: the same GH pulse produced by tesamorelin encounters more receptors, producing a larger tissue-level anabolic signal. BPC-157 also independently promotes vascular endothelial growth factor (VEGF) expression [3], which may speed nutrient delivery to recovering tissue while tesamorelin shifts substrate utilization toward fat oxidation [1].

No head-to-head or combination RCT has confirmed this additive model. The mechanism is plausible but unproven in humans.

Tesamorelin Dosing: FDA-Labeled vs. Off-Label Practice

The FDA-approved dose is 2 mg subcutaneous once daily, injected into the abdomen [6]. This label applies specifically to HIV-associated lipodystrophy. Off-label use for body composition or anti-aging purposes uses the same 2 mg dose in most practitioner-reported protocols, though some clinicians reduce to 1 mg/day for patients who show IGF-1 values that exceed the age-adjusted upper reference range.

Injection Timing

Tesamorelin is conventionally injected at bedtime to coincide with the largest physiological GH pulse, which occurs 60 to 90 minutes after sleep onset [2]. Subcutaneous administration into periumbilical fat is standard per the Egrifta SV prescribing information [6].

Monitoring IGF-1

The Endocrine Society guideline recommends targeting an IGF-1 level in the upper-normal quartile for age and sex [2]. IGF-1 should be checked at baseline, at 8 weeks, and at 16 to 20 weeks. Doses that push IGF-1 above the age-adjusted reference range increase the theoretical risk of glucose intolerance and, with chronic supraphysiological exposure, may raise concerns about tissue proliferation [2].

Glucose Monitoring

Tesamorelin raises fasting glucose by a mean of 3.2 mg/dL versus placebo in Phase III data [1]. Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) need closer monitoring. The FDA label states tesamorelin is contraindicated in patients with active malignancy and should be used with caution in those with diabetes [6].

BPC-157 Dosing in the Stack Context

No human dosing study has established a minimum effective dose for BPC-157 in any indication. The investigational doses used in most animal efficacy studies translate (by FDA allometric scaling guidance) to approximately 2 to 10 mcg/kg in a 70-kg human, or roughly 140 to 700 mcg/day [7]. Practitioner-reported protocols most commonly use 200 to 500 mcg subcutaneous once daily or split into two 200 mcg doses morning and evening.

Oral vs. Subcutaneous Route

Rodent studies demonstrate gut-protective effects with both oral and subcutaneous BPC-157, with oral administration preferentially concentrating the peptide in the gastrointestinal tract [3]. For systemic or musculoskeletal indications in the stack context (where tesamorelin's metabolic effect is the primary driver), subcutaneous injection is the more common route among practitioners.

Injection Site Selection

BPC-157 is typically injected subcutaneously near the site of a target injury (perilesional) or in the abdomen for systemic effect. When stacking with tesamorelin, many protocols inject BPC-157 in the morning and tesamorelin in the evening to separate the injections in time and reduce any theoretical receptor-level competition.

Duration and Cycling

Animal tendon-healing studies show significant structural improvement within 14 days of daily BPC-157 at relevant doses [4]. Practitioners typically run BPC-157 for 12 to 16 weeks, then cycle off for 4 weeks. Tesamorelin trials ran for 26 weeks continuously in the Phase III design [1]. In off-label practice, cycles of 20 to 26 weeks followed by 4 to 6 weeks off are reported to preserve pituitary sensitivity to endogenous GHRH.

The Combined Protocol: Timing, Labs, and Cycling

Combining these two peptides requires attention to injection timing, lab monitoring intervals, and cycle structure. The table below shows a representative 24-week protocol framework.

Week-by-Week Structure

Weeks 1 to 12 (Initiation Phase): Tesamorelin 2 mg subcutaneous every evening. BPC-157 250 mcg subcutaneous every morning. Check baseline IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel (CMP) before starting. Repeat IGF-1 and fasting glucose at week 8.

Weeks 13 to 16 (BPC-157 Washout): Continue tesamorelin 2 mg every evening. Discontinue BPC-157. This period allows assessment of tesamorelin's stand-alone effect on body composition and IGF-1. Repeat IGF-1 at week 16.

Weeks 17 to 24 (Continuation and Assessment): Tesamorelin 2 mg every evening continued. Optional: reintroduce BPC-157 at week 17 if musculoskeletal or gut recovery goals remain active. Full labs (IGF-1, fasting glucose, HbA1c, CMP) at week 24.

Weeks 25 to 28 (Off-Cycle): Discontinue both peptides. Allow 4 to 6 weeks off before reassessing. In the Phase III extension study, VAT reduction was maintained for up to 52 weeks on tesamorelin but rebounded within 26 weeks of discontinuation [1].

Lab Monitoring Schedule

Monitoring frequency mirrors the Endocrine Society's GH therapy guidelines more closely than any BPC-157-specific guidance (which does not exist in published human data). IGF-1 should be checked at baseline, 8 weeks, 16 weeks, and end-of-cycle [2]. Fasting glucose and HbA1c at baseline and every 12 weeks are reasonable given tesamorelin's modest hyperglycemic effect [6].

Contraindications and Cautions

Tesamorelin is contraindicated in pregnancy, active malignancy, and disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor, cranial irradiation) [6]. BPC-157 carries no established human contraindication list because it has not completed clinical trials, but the same logic applies: active malignancy warrants avoidance of any growth-promoting peptide. Patients with a personal or strong family history of colorectal, prostate, or breast cancer should discuss the theoretical IGF-1-related proliferative risk with their oncologist before starting tesamorelin [2].

Evidence Quality: What We Know and What We Do Not

Most peptide-stack protocols, including this one, sit at the intersection of FDA-approved pharmacology (tesamorelin) and animal/mechanistic data (BPC-157). Being explicit about that hierarchy matters.

What Has Strong Evidence

Tesamorelin 2 mg/day reduces VAT by roughly 18% at 26 weeks in HIV-positive adults with lipodystrophy; this is supported by two Phase III RCTs and confirmed in extension data [1]. The drug's IGF-1-raising effect is reproducible and dose-consistent. The FDA label, prescribing information, and pharmacokinetic profile are fully characterized [6].

What Has Moderate Evidence

BPC-157's angiogenic and tendon-healing effects are reproducible across multiple rodent models from independent laboratories [3, 4]. A 2023 review in Biomedicines analyzed 30 animal studies and found consistent reduction in inflammation markers and improvement in structural healing outcomes across gut, tendon, and bone models [8]. The consistency across labs and species gives moderate confidence that the mechanism is real, even without human trial data.

What Is Speculative

The additive or synergistic body-composition benefit of combining BPC-157 with tesamorelin has no direct evidence. The GHR-upregulation hypothesis (BPC-157 increases receptor density, tesamorelin provides more ligand) is mechanistically coherent but extrapolated from separate lines of rodent research [4]. Practitioners who report enhanced results with the combination cannot rule out placebo effect, lifestyle changes, or the independent effect of tesamorelin alone.

The journal Peptides published a 2021 commentary by Sikiric et al. Noting that BPC-157's pleiotropic effects across organ systems make it "difficult to attribute benefit to a single pathway" and calling for phase II trials to define dose, route, and indication in humans [9].

Side Effects and Risk Management

Tesamorelin Side Effects

Across the Phase III program (N=816), the most common adverse events were injection-site reactions (25.5%), arthralgia (13.3%), and peripheral edema (9.7%) [1]. Glucose elevation was modest but statistically significant. Patients who developed IGF-1 values above the upper limit of normal had a higher rate of glucose abnormalities, which supports the IGF-1 monitoring protocol described above [2].

BPC-157 Side Effects

No human safety database exists beyond the incomplete IBD Phase II trial [5]. Animal toxicology studies have not identified organ toxicity at doses up to 10 times the effective dose in rodent models [3]. Nausea and transient fatigue are the most frequently reported effects in practitioner case series, but these reports carry significant bias and no control group.

Drug Interactions

Tesamorelin may reduce the efficacy of cortisone, prednisone, and other glucocorticoids by antagonizing their anti-inflammatory effect at the pituitary level [6]. BPC-157 has been shown in rodent models to modulate dopaminergic and serotonergic pathways [4], which raises a theoretical interaction flag with SSRIs, SNRIs, and antipsychotics. No human pharmacokinetic interaction data exist for BPC-157 with any drug class.

Who Should Not Use This Stack

Patients with active cancer, pregnancy, or disrupted hypothalamic-pituitary-adrenal axis are excluded by the tesamorelin label alone [6]. Patients with type 2 diabetes on insulin or sulfonylureas need closer glucose monitoring given the additive hyperglycemic risk. Anyone <18 years old should not use either compound outside a clinical trial setting.

Sourcing, Compounding, and Legal Considerations

Egrifta SV is a commercially manufactured prescription product available through licensed U.S. Pharmacies. BPC-157 is not FDA-approved for any indication and is not available through licensed compounding pharmacies under the current FDA enforcement posture on peptides [10]. The FDA's 2023 guidance update placed BPC-157 on the list of peptides that may not be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [10]. Patients obtaining BPC-157 from research chemical vendors assume legal and quality-control risks that a licensed pharmacy eliminates.

The purity, sterility, and actual peptide content of research-grade BPC-157 vary substantially. A 2019 analytical study tested 14 commercial peptide products and found that 7 (50%) had peptide content deviating more than 10% from the labeled amount, and 3 (21%) showed evidence of microbial contamination [11].

Practical Injection Technique

Both peptides are prepared as lyophilized powder reconstituted with bacteriostatic water. Standard reconstitution for tesamorelin follows the Egrifta SV package insert: add 2.1 mL of sterile water to the 2 mg vial and inject gently [6]. BPC-157 is typically reconstituted to a concentration of 500 mcg/mL, so a 250 mcg dose equals a 0.5 mL draw with a 29-gauge, 0.5-inch insulin syringe.

Injection-site rotation reduces the risk of subcutaneous lipodystrophy, which is ironic given that tesamorelin's own indication involves correcting lipodystrophy. Rotating among four quadrants of the lower abdomen on a weekly schedule is a practical approach.

Refrigeration at 2 to 8°C is required for reconstituted tesamorelin; it is stable for up to 3 hours at room temperature post-reconstitution [6]. BPC-157 stability data are limited to manufacturer claims for lyophilized powder; reconstituted peptide should be used within 30 days if refrigerated, consistent with general peptide handling guidance from compounding pharmacies.

Interpreting Results: What to Expect and When

Tesamorelin's VAT reduction becomes measurable by CT or DEXA at 12 weeks and reaches statistical significance versus placebo by week 26 in trial data [1]. Subjectively, patients often report improved energy and reduced abdominal fullness by weeks 4 to 6. IGF-1 rises within 4 to 8 weeks and can be used as an early pharmacodynamic marker.

BPC-157's effects on tendon pain and gut symptoms, in animal models and practitioner reports, appear within 2 to 4 weeks at doses of 200 to 500 mcg/day [4]. These timelines are consistent with the cellular proliferation kinetics seen in the rodent healing studies, though direct human extrapolation remains speculative.

A patient who completes 12 weeks on the combined protocol and sees no IGF-1 rise should prompt a review of tesamorelin product authenticity and injection technique before attributing failure to the stack design.